Biodefense in the Age of Synthetic Biology – Tom Slezak

Biodefense in the Age of
Synthetic Biology
Tom Slezak, KPATH Scientific, LLC
(Committee Member)
Catalyst Workshop
February 22, 2020
(Report released in June 2018)
Committee
Michael Imperiale, Ph.D. (Chair)
University of Michigan
Charles Haas, Ph.D.
Drexel University
Patrick Boyle, Ph.D.
Ginkgo Bioworks
Joseph Kanabrocki, Ph.D.
University of Chicago
Peter A. Carr, Ph.D.
MIT Lincoln Laboratory
Kara Morgan, Ph.D.
Quant Policy Strategies, LLC
Douglas Densmore, Ph.D.
Boston University
Kristala Jones Prather, Ph.D.
Massachusetts Institute of Technology
Diane DiEuliis, Ph.D.
National Defense University
Jill Taylor, Ph.D.
New York State Department of Health
Andrew Ellington, Ph.D.
University of Texas
Thomas R. Slezak, M.S.
Lawrence Livermore National Laboratory
Gigi Kwik Gronvall, Ph.D.
John Hopkins Bloomberg School of
Public Health
National Academies Staff
Marilee Shelton Davenport, Ph.D. Study Director
Katherine Bowman, Ph.D., Sr. Program Officer
Jenna Ogilvie, Research Associate
Jarrett Nguyen, Senior Program Assistant
Report’s Task
1. Develop a strategic framework to guide assessment
of security vulnerabilities associated with advances in
biotechnology, with emphasis on synthetic biology:
• What are security concerns on the horizon?
• What are time frames of development of these concerns?
• What are potential options for mitigating these concerns?
2. Use the framework to assess a set of synthetic biology-
enabled capabilities
(Report sponsored by the U.S. Department of Defense's Chemical and Biological Defense
Program)
Framework for
evaluating
security
concerns
Analysis of Potential Capabilities
Assessed 12 capabilities related to:
• Synthesis and modification of pathogens
• Production of chemicals, biochemicals and toxins
• Modulation of human physiology
Biotechnology in the age of synthetic biology expands
the landscape of potential defense concerns
Ongoing strategies for chemical and biological defense
remain relevant in the age of synthetic biology
Also need approaches to account for the broader
capabilities enabled by synthetic biology, now and into the
future
Overarching Recommendation
Relative Concern of
Capabilities Assessed
Pathogens
Synthetic biology is expected to:
• expand the range of what could be produced
• decrease the amount of time required
• expand the range of actors
Creation and manipulation of pathogens is facilitated by
increasingly accessible technologies and starting materials,
including DNA sequences in public databases. A wide range of
pathogen characteristics could be explored as part of such efforts.
Chemicals, Biochemicals, and Toxins
Synthetic biology:
• blurs the line between chemical and biological weapons
High potency molecules that can be produced through simple
genetic pathways are of greatest concern, as they could conceivably
be developed with modest resources and organizational footprint.
Through synthetic biology:
• may be possible to modulate human physiology in novel
ways
These include physiological changes that differ from the typical
effects of known pathogens and chemical agents. Synthetic biology
expands the landscape by potentially allowing the delivery of
biochemicals by a biological agent, and by potentially allowing the
engineering of the microbiome or immune system. While unlikely
today, these types of manipulations may become more feasible as
knowledge of complex systems grows.
Modulation of Human Physiology
Bottlenecks and Barriers
Some malicious applications may not seem plausible now but
could become achievable if certain barriers are overcome.
It is important to continue to monitor advances in
biotechnology that may lower these barriers.
Barriers include:
• Knowledge barriers, as is the case for building a novel pathogen
• Technological barriers, as in engineering complex biosynthetic
pathways into bacteria or re-creating known bacterial pathogens
Convergent technologies from outside of synthetic biology may
assist in overcoming some of the barriers in areas such as
production, fidelity and testing, delivery, targeting
– Gene therapy
– Nanotechnology
– Automation
– Additive manufacturing
– Health informatics
Related Developments May Impact Ability
to Use Synthetic Biology-Enabled Weapons
Synthetic Biology Poses Mitigation Challenges
Many traditional approaches to biological and chemical defense
preparedness will be relevant to synthetic biology. But synthetic
biology also presents new challenges
• The potential unpredictability related to how a synthetic biology-
enabled weapon could manifest creates an added challenge to
monitoring and detection
• Range of strategies needed to prepare and respond
• Continue exploring strategies that are applicable to a wide range of chemical and
biodefense threats
• Evaluate the infrastructure that informs population-based surveillance, identification,
and notification of both natural and purposeful health threats
• Consider strategies that manage emerging risk better than current agent-based lists
and access control approaches
Exploration Areas: Potential Opportunities to
Advance Mitigation Capabilities
• Developing capabilities to detect unusual ways in which a
synthetic biology-enabled weapon may manifest
• Harnessing computational approaches for mitigation
• Leveraging synthetic biology to advance detection, therapeutics,
vaccines, and other medical countermeasures
More Information
synbiodefense@nas.edu
Download report and 4-page brief:
http://nas-sites.org/dels/studies/strategies-
for-identifying-and-addressing-
vulnerabilities-posed-by-synthetic-biology/
Staff
Marilee Shelton-Davenport, PhD; Study Director mshelton@nas.edu
Katherine Bowman, PhD; Board on Life Sciences kbowman@nas.edu
Discussion Question:
• Consider both bio-error and bio-terror.
• Consider what we don’t know about the organisms we are
manipulating. What assumptions about safety might turn out to be
incorrect?
How might YOUR work be affected
by an increased understanding of
potential Synthetic Biology risks?
1 of 16

Recommended

CETR - Rutgers NJ Medical School by
CETR - Rutgers NJ Medical SchoolCETR - Rutgers NJ Medical School
CETR - Rutgers NJ Medical SchoolRiccardo Russo
112 views2 slides
PGCA_Agenda 2017 by
PGCA_Agenda 2017PGCA_Agenda 2017
PGCA_Agenda 2017Rita Jeswant
294 views13 slides
The Global Micorbial Identifier (GMI) initiative - and its working groups by
The Global Micorbial Identifier (GMI) initiative - and its working groupsThe Global Micorbial Identifier (GMI) initiative - and its working groups
The Global Micorbial Identifier (GMI) initiative - and its working groupsExternalEvents
1.6K views11 slides
GET Conference at Arizona State University (25 May 2016) by
GET Conference at Arizona State University (25 May 2016)GET Conference at Arizona State University (25 May 2016)
GET Conference at Arizona State University (25 May 2016)CASI, Arizona State University
456 views78 slides
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo... by
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...OECD Environment
92 views12 slides
The challenge of gene therapy by
The challenge of gene therapyThe challenge of gene therapy
The challenge of gene therapycreativebiolabs11
68 views3 slides

More Related Content

What's hot

Short courses in food safety risk assessment by
Short courses in food safety risk assessmentShort courses in food safety risk assessment
Short courses in food safety risk assessmentEFSA EU
1.9K views29 slides
How bioinformatic and sequencing data might inform the regulatory process - O... by
How bioinformatic and sequencing data might inform the regulatory process - O...How bioinformatic and sequencing data might inform the regulatory process - O...
How bioinformatic and sequencing data might inform the regulatory process - O...OECD Environment
142 views13 slides
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio... by
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...ExternalEvents
991 views25 slides
Toxicology by
ToxicologyToxicology
ToxicologyAbinaya536
133 views20 slides
CI4CC Cancer Informatics Perspectives by
CI4CC Cancer Informatics PerspectivesCI4CC Cancer Informatics Perspectives
CI4CC Cancer Informatics PerspectivesWarren Kibbe
704 views28 slides
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity Studies Toxicologic... by
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicologic...Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicologic...
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity Studies Toxicologic...Dmitri Popov
106 views8 slides

What's hot(20)

Short courses in food safety risk assessment by EFSA EU
Short courses in food safety risk assessmentShort courses in food safety risk assessment
Short courses in food safety risk assessment
EFSA EU1.9K views
How bioinformatic and sequencing data might inform the regulatory process - O... by OECD Environment
How bioinformatic and sequencing data might inform the regulatory process - O...How bioinformatic and sequencing data might inform the regulatory process - O...
How bioinformatic and sequencing data might inform the regulatory process - O...
OECD Environment142 views
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio... by ExternalEvents
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
ExternalEvents991 views
CI4CC Cancer Informatics Perspectives by Warren Kibbe
CI4CC Cancer Informatics PerspectivesCI4CC Cancer Informatics Perspectives
CI4CC Cancer Informatics Perspectives
Warren Kibbe704 views
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity Studies Toxicologic... by Dmitri Popov
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicologic...Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicologic...
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity Studies Toxicologic...
Dmitri Popov106 views
Global surveillance One World – One Health by ExternalEvents
Global surveillance  One World – One HealthGlobal surveillance  One World – One Health
Global surveillance One World – One Health
ExternalEvents1.2K views
How Can We Make Genomic Epidemiology a Widespread Reality? - William Hsiao by William Hsiao
How Can We Make Genomic Epidemiology a Widespread Reality?  - William HsiaoHow Can We Make Genomic Epidemiology a Widespread Reality?  - William Hsiao
How Can We Make Genomic Epidemiology a Widespread Reality? - William Hsiao
William Hsiao348 views
Fundamentals of bioethics and biosafety by Mahmoud Bahnasi
Fundamentals of bioethics and biosafetyFundamentals of bioethics and biosafety
Fundamentals of bioethics and biosafety
Mahmoud Bahnasi538 views
Clinical Genomics and Medicine by Warren Kibbe
Clinical Genomics and MedicineClinical Genomics and Medicine
Clinical Genomics and Medicine
Warren Kibbe2.7K views
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017) by Elia Brodsky
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)
Elia Brodsky229 views
The study of modes of action: the AOP by EFSA EU
The study of modes of action: the AOPThe study of modes of action: the AOP
The study of modes of action: the AOP
EFSA EU947 views
Antimicrobial Stewardship ,Heba Abdallatif,BCPS by Heba Abd Allatif
Antimicrobial Stewardship  ,Heba Abdallatif,BCPSAntimicrobial Stewardship  ,Heba Abdallatif,BCPS
Antimicrobial Stewardship ,Heba Abdallatif,BCPS
Heba Abd Allatif1.2K views
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com... by Warren Kibbe
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...
Warren Kibbe857 views
Antimicrobial Stewardship Program by saskohc
Antimicrobial Stewardship ProgramAntimicrobial Stewardship Program
Antimicrobial Stewardship Program
saskohc2.3K views

Similar to Biodefense in the Age of Synthetic Biology – Tom Slezak

Bioinformatics by
BioinformaticsBioinformatics
BioinformaticsDr. Siddhi Upadhyay
7.8K views21 slides
Synthetic Biology.pptx by
Synthetic Biology.pptxSynthetic Biology.pptx
Synthetic Biology.pptxShubNoor4
9 views15 slides
Nw biotech fundamentals day 1 session 5 life sciences by
Nw biotech fundamentals day 1 session 5   life sciencesNw biotech fundamentals day 1 session 5   life sciences
Nw biotech fundamentals day 1 session 5 life sciencesNicholas Weston Lawyers
726 views77 slides
Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy by
Current Concepts in Laboratory Testing to Guide Antimicrobial TherapyCurrent Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Current Concepts in Laboratory Testing to Guide Antimicrobial TherapyPathogens Outlook
648 views19 slides
Basic of bioinformatics by
Basic of bioinformaticsBasic of bioinformatics
Basic of bioinformaticsJayati Shrivastava
225 views37 slides
introduction to bioinfromatics.pptx by
introduction to bioinfromatics.pptxintroduction to bioinfromatics.pptx
introduction to bioinfromatics.pptxAbelPhilipJoseph
4 views35 slides

Similar to Biodefense in the Age of Synthetic Biology – Tom Slezak(20)

Synthetic Biology.pptx by ShubNoor4
Synthetic Biology.pptxSynthetic Biology.pptx
Synthetic Biology.pptx
ShubNoor49 views
Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy by Pathogens Outlook
Current Concepts in Laboratory Testing to Guide Antimicrobial TherapyCurrent Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Pathogens Outlook648 views
Computational Biology and Bioinformatics by Sharif Shuvo
Computational Biology and BioinformaticsComputational Biology and Bioinformatics
Computational Biology and Bioinformatics
Sharif Shuvo11.4K views
Genomics and proteomics by shreeman by shreeman cs
Genomics and proteomics by shreemanGenomics and proteomics by shreeman
Genomics and proteomics by shreeman
shreeman cs3.4K views
Bioinformatics by JTADrexel
BioinformaticsBioinformatics
Bioinformatics
JTADrexel120.5K views
Bioinformatics in drug discovery by KAUSHAL SAHU
Bioinformatics in drug discoveryBioinformatics in drug discovery
Bioinformatics in drug discovery
KAUSHAL SAHU4.2K views
Drugdiscoveryanddevelopment by khadga raj by Khadga Raj
Drugdiscoveryanddevelopment by khadga rajDrugdiscoveryanddevelopment by khadga raj
Drugdiscoveryanddevelopment by khadga raj
Khadga Raj150 views
Probiotic symposium chennai 3 dec 2016 by neerjayakult
Probiotic symposium chennai 3 dec 2016Probiotic symposium chennai 3 dec 2016
Probiotic symposium chennai 3 dec 2016
neerjayakult489 views
Role of bioinformatics in drug designing by W Roseybala Devi
Role of bioinformatics in drug designingRole of bioinformatics in drug designing
Role of bioinformatics in drug designing
W Roseybala Devi5.1K views
Bioethics and biosafety issues by HarshaAsiwal
Bioethics and biosafety issuesBioethics and biosafety issues
Bioethics and biosafety issues
HarshaAsiwal468 views
Bioinformatic in drug designing by Salman Khan
Bioinformatic in drug designingBioinformatic in drug designing
Bioinformatic in drug designing
Salman Khan1.5K views
Functional Analysis & Screening Technologies Congress by James Prudhomme
Functional Analysis & Screening Technologies CongressFunctional Analysis & Screening Technologies Congress
Functional Analysis & Screening Technologies Congress
James Prudhomme823 views
Drug Devel Ment by Med Bee
Drug Devel MentDrug Devel Ment
Drug Devel Ment
Med Bee331 views
Super computing 19 Cancer Computing Workshop Keynote by Warren Kibbe
Super computing 19 Cancer Computing Workshop KeynoteSuper computing 19 Cancer Computing Workshop Keynote
Super computing 19 Cancer Computing Workshop Keynote
Warren Kibbe204 views

More from Catalyst Biosummit

Measuring Cultures of Responsibility in the Life Sciences – Daniel Greene by
Measuring Cultures of Responsibility in the Life Sciences – Daniel GreeneMeasuring Cultures of Responsibility in the Life Sciences – Daniel Greene
Measuring Cultures of Responsibility in the Life Sciences – Daniel GreeneCatalyst Biosummit
119 views14 slides
Broad-Spectrum Antivirals: An Essential Tool for Biosecurity by
Broad-Spectrum Antivirals: An Essential Tool for BiosecurityBroad-Spectrum Antivirals: An Essential Tool for Biosecurity
Broad-Spectrum Antivirals: An Essential Tool for BiosecurityCatalyst Biosummit
186 views16 slides
Biosecurity Challenges in the Genome Engineering Space – Beth Vitalis by
Biosecurity Challenges in the Genome Engineering Space – Beth VitalisBiosecurity Challenges in the Genome Engineering Space – Beth Vitalis
Biosecurity Challenges in the Genome Engineering Space – Beth VitalisCatalyst Biosummit
160 views12 slides
A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua... by
A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua...A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua...
A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua...Catalyst Biosummit
225 views29 slides
The Germy Paradox – Georgia Ray by
The Germy Paradox – Georgia RayThe Germy Paradox – Georgia Ray
The Germy Paradox – Georgia RayCatalyst Biosummit
168 views22 slides
Technologies to Address Global Catastrophic Biological Risks – Tara Kirk Sell by
Technologies to Address Global Catastrophic Biological Risks – Tara Kirk SellTechnologies to Address Global Catastrophic Biological Risks – Tara Kirk Sell
Technologies to Address Global Catastrophic Biological Risks – Tara Kirk SellCatalyst Biosummit
241 views35 slides

More from Catalyst Biosummit(6)

Measuring Cultures of Responsibility in the Life Sciences – Daniel Greene by Catalyst Biosummit
Measuring Cultures of Responsibility in the Life Sciences – Daniel GreeneMeasuring Cultures of Responsibility in the Life Sciences – Daniel Greene
Measuring Cultures of Responsibility in the Life Sciences – Daniel Greene
Catalyst Biosummit119 views
Broad-Spectrum Antivirals: An Essential Tool for Biosecurity by Catalyst Biosummit
Broad-Spectrum Antivirals: An Essential Tool for BiosecurityBroad-Spectrum Antivirals: An Essential Tool for Biosecurity
Broad-Spectrum Antivirals: An Essential Tool for Biosecurity
Catalyst Biosummit186 views
Biosecurity Challenges in the Genome Engineering Space – Beth Vitalis by Catalyst Biosummit
Biosecurity Challenges in the Genome Engineering Space – Beth VitalisBiosecurity Challenges in the Genome Engineering Space – Beth Vitalis
Biosecurity Challenges in the Genome Engineering Space – Beth Vitalis
Catalyst Biosummit160 views
A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua... by Catalyst Biosummit
A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua...A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua...
A Metagenomic Perspective on Ecology, Biosecurity, and Public Health – Joshua...
Catalyst Biosummit225 views
Technologies to Address Global Catastrophic Biological Risks – Tara Kirk Sell by Catalyst Biosummit
Technologies to Address Global Catastrophic Biological Risks – Tara Kirk SellTechnologies to Address Global Catastrophic Biological Risks – Tara Kirk Sell
Technologies to Address Global Catastrophic Biological Risks – Tara Kirk Sell
Catalyst Biosummit241 views

Recently uploaded

Gastro-retentive drug delivery systems.pptx by
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptxABG
233 views32 slides
Biomedicine & Pharmacotherapy by
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & PharmacotherapyTrustlife
220 views12 slides
NeuroGASTRO-2023-Programme.pdf by
NeuroGASTRO-2023-Programme.pdfNeuroGASTRO-2023-Programme.pdf
NeuroGASTRO-2023-Programme.pdfOanaTimofte3
11 views31 slides
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends by
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trendsmuskansbl01
59 views15 slides
Obesity.pdf by
Obesity.pdfObesity.pdf
Obesity.pdfRutvikunvar Raualji (PT)
143 views30 slides
communication and nurse patient relationship by Tamanya Samui.pdf by
communication and nurse patient relationship by Tamanya Samui.pdfcommunication and nurse patient relationship by Tamanya Samui.pdf
communication and nurse patient relationship by Tamanya Samui.pdfTamanyaSamui1
33 views32 slides

Recently uploaded(20)

Gastro-retentive drug delivery systems.pptx by ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG233 views
Biomedicine & Pharmacotherapy by Trustlife
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy
Trustlife220 views
NeuroGASTRO-2023-Programme.pdf by OanaTimofte3
NeuroGASTRO-2023-Programme.pdfNeuroGASTRO-2023-Programme.pdf
NeuroGASTRO-2023-Programme.pdf
OanaTimofte311 views
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends by muskansbl01
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
muskansbl0159 views
communication and nurse patient relationship by Tamanya Samui.pdf by TamanyaSamui1
communication and nurse patient relationship by Tamanya Samui.pdfcommunication and nurse patient relationship by Tamanya Samui.pdf
communication and nurse patient relationship by Tamanya Samui.pdf
TamanyaSamui133 views
Impact of Public Health Postnatal Home Visiting in NB on Breastfeeding among ... by DataNB
Impact of Public Health Postnatal Home Visiting in NB on Breastfeeding among ...Impact of Public Health Postnatal Home Visiting in NB on Breastfeeding among ...
Impact of Public Health Postnatal Home Visiting in NB on Breastfeeding among ...
DataNB14 views
Calcutta Clinical Course - Allen College of Homoeopathy by Allen College
Calcutta Clinical Course - Allen College of HomoeopathyCalcutta Clinical Course - Allen College of Homoeopathy
Calcutta Clinical Course - Allen College of Homoeopathy
Allen College94 views
Explore new Frontiers in Medicine with AI.pdf by Anne Marie
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdf
Anne Marie18 views
Buccoadhesive drug delivery System.pptx by ABG
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptx
ABG167 views
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP by MohamadAlhes
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDPChronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
MohamadAlhes89 views
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx by ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG120 views
CCDI Kibbe Wake Forest University Dec 2023.pptx by Warren Kibbe
CCDI Kibbe Wake Forest University Dec 2023.pptxCCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptx
Warren Kibbe12 views
Trustlife Türkiye - Güncel Platform Yapısı by Trustlife
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform Yapısı
Trustlife43 views

Biodefense in the Age of Synthetic Biology – Tom Slezak

  • 1. Biodefense in the Age of Synthetic Biology Tom Slezak, KPATH Scientific, LLC (Committee Member) Catalyst Workshop February 22, 2020 (Report released in June 2018)
  • 2. Committee Michael Imperiale, Ph.D. (Chair) University of Michigan Charles Haas, Ph.D. Drexel University Patrick Boyle, Ph.D. Ginkgo Bioworks Joseph Kanabrocki, Ph.D. University of Chicago Peter A. Carr, Ph.D. MIT Lincoln Laboratory Kara Morgan, Ph.D. Quant Policy Strategies, LLC Douglas Densmore, Ph.D. Boston University Kristala Jones Prather, Ph.D. Massachusetts Institute of Technology Diane DiEuliis, Ph.D. National Defense University Jill Taylor, Ph.D. New York State Department of Health Andrew Ellington, Ph.D. University of Texas Thomas R. Slezak, M.S. Lawrence Livermore National Laboratory Gigi Kwik Gronvall, Ph.D. John Hopkins Bloomberg School of Public Health National Academies Staff Marilee Shelton Davenport, Ph.D. Study Director Katherine Bowman, Ph.D., Sr. Program Officer Jenna Ogilvie, Research Associate Jarrett Nguyen, Senior Program Assistant
  • 3. Report’s Task 1. Develop a strategic framework to guide assessment of security vulnerabilities associated with advances in biotechnology, with emphasis on synthetic biology: • What are security concerns on the horizon? • What are time frames of development of these concerns? • What are potential options for mitigating these concerns? 2. Use the framework to assess a set of synthetic biology- enabled capabilities (Report sponsored by the U.S. Department of Defense's Chemical and Biological Defense Program)
  • 5. Analysis of Potential Capabilities Assessed 12 capabilities related to: • Synthesis and modification of pathogens • Production of chemicals, biochemicals and toxins • Modulation of human physiology
  • 6. Biotechnology in the age of synthetic biology expands the landscape of potential defense concerns Ongoing strategies for chemical and biological defense remain relevant in the age of synthetic biology Also need approaches to account for the broader capabilities enabled by synthetic biology, now and into the future Overarching Recommendation
  • 8. Pathogens Synthetic biology is expected to: • expand the range of what could be produced • decrease the amount of time required • expand the range of actors Creation and manipulation of pathogens is facilitated by increasingly accessible technologies and starting materials, including DNA sequences in public databases. A wide range of pathogen characteristics could be explored as part of such efforts.
  • 9. Chemicals, Biochemicals, and Toxins Synthetic biology: • blurs the line between chemical and biological weapons High potency molecules that can be produced through simple genetic pathways are of greatest concern, as they could conceivably be developed with modest resources and organizational footprint.
  • 10. Through synthetic biology: • may be possible to modulate human physiology in novel ways These include physiological changes that differ from the typical effects of known pathogens and chemical agents. Synthetic biology expands the landscape by potentially allowing the delivery of biochemicals by a biological agent, and by potentially allowing the engineering of the microbiome or immune system. While unlikely today, these types of manipulations may become more feasible as knowledge of complex systems grows. Modulation of Human Physiology
  • 11. Bottlenecks and Barriers Some malicious applications may not seem plausible now but could become achievable if certain barriers are overcome. It is important to continue to monitor advances in biotechnology that may lower these barriers. Barriers include: • Knowledge barriers, as is the case for building a novel pathogen • Technological barriers, as in engineering complex biosynthetic pathways into bacteria or re-creating known bacterial pathogens
  • 12. Convergent technologies from outside of synthetic biology may assist in overcoming some of the barriers in areas such as production, fidelity and testing, delivery, targeting – Gene therapy – Nanotechnology – Automation – Additive manufacturing – Health informatics Related Developments May Impact Ability to Use Synthetic Biology-Enabled Weapons
  • 13. Synthetic Biology Poses Mitigation Challenges Many traditional approaches to biological and chemical defense preparedness will be relevant to synthetic biology. But synthetic biology also presents new challenges • The potential unpredictability related to how a synthetic biology- enabled weapon could manifest creates an added challenge to monitoring and detection • Range of strategies needed to prepare and respond • Continue exploring strategies that are applicable to a wide range of chemical and biodefense threats • Evaluate the infrastructure that informs population-based surveillance, identification, and notification of both natural and purposeful health threats • Consider strategies that manage emerging risk better than current agent-based lists and access control approaches
  • 14. Exploration Areas: Potential Opportunities to Advance Mitigation Capabilities • Developing capabilities to detect unusual ways in which a synthetic biology-enabled weapon may manifest • Harnessing computational approaches for mitigation • Leveraging synthetic biology to advance detection, therapeutics, vaccines, and other medical countermeasures
  • 15. More Information synbiodefense@nas.edu Download report and 4-page brief: http://nas-sites.org/dels/studies/strategies- for-identifying-and-addressing- vulnerabilities-posed-by-synthetic-biology/ Staff Marilee Shelton-Davenport, PhD; Study Director mshelton@nas.edu Katherine Bowman, PhD; Board on Life Sciences kbowman@nas.edu
  • 16. Discussion Question: • Consider both bio-error and bio-terror. • Consider what we don’t know about the organisms we are manipulating. What assumptions about safety might turn out to be incorrect? How might YOUR work be affected by an increased understanding of potential Synthetic Biology risks?

Editor's Notes

  1. New report released by the U.S. National Academies of Sciences, Engineering, and Medicine in June 2018
  2. Highlight that committee has expertise in a number of areas – Various areas of synthetic biology; microbiology; data analytics and biodesign software; public health; technical forecasting and threat assessment; biosafety and biosecurity
  3. This is a streamlined SOT. The full task is in the report. (Report is not be a threat assessment) To assist the U.S. Department of Defense's Chemical and Biological Defense Program (CBDP), The National Academies of Sciences, Engineering, and Medicine will appoint an ad hoc committee to address the changing nature of the biodefense threat in the age of synthetic biology. Specifically, the focus of the study will be the manipulation of biological functions, systems, or microorganisms resulting in the production of a disease-causing agents or toxins. The study will be conducted in two primary phases. Initially, the committee will develop a strategic framework to guide an assessment of the potential security vulnerabilities related to advances in biology and biotechnology, with a particular emphasis on synthetic biology. The framework will focus on how to address the following three questions: What are the possible security concerns with regard to synthetic biology that are on the horizon? What are the time frames of development of these concerns? What are our options for mitigating these potential concerns? The committee will publish a brief interim, public report outlining the developed framework. This framework will not be a threat assessment, but rather, will focus on ways to identify scientific developments to enable opportunities that have the potential to mitigate threats posed by synthetic biology in the near-, mid-, and long-term, with the specific time frames defined by the committee. The framework will lay out how best to consider the trajectory of scientific advances, identify potential areas of vulnerability and predict promising mitigation opportunities. In Phase 2 of the study, the committee refined its strategic framework and used the framework to generate an assessment of vulnerabilities posed by synthetic biology.   The report is currently in security review with DOD. It will be briefed to DOD and partner agencies, to interested congressional committees, and disseminated to the public including the synthetic biology communities once it has cleared security review Phase 3: After the study portion is completed and the final report is released, the committee will organize a classified workshop to present its findings to the biodefense community and selected members of the synthetic biology community and contribute to the biodefense community's discussion of potential vulnerabilities and mitigation options. A brief proceedings will be prepared by a rapporteur to capture the discussion at the workshop. The brief proceedings will not contain any consensus finding or recommendations of the committee.
  4. The committee acknowledges the tremendous value of synthetic biology to a number of societal goals but made no attempt to compare the size or nature of those benefits with the potential risks. It is not the intent of the committee or study sponsor to in any way imply that research efforts that use synthetic biology approaches should be curtailed. Benefits of Synthetic Biology   The field of synthetic biology opens tremendous possibilities for the application of biotechnology to improve human well-being, as well as the health of animals, plants, and the environment. Such applications hold substantial economic potential. For example, annual U.S. revenues from genetically engineered plants and microbes are estimated to exceed $300 billion, and industrial biotechnology (the use of biological components to generate industrial products) is estimated to account for more than $115 billion in annual U.S. revenues. New applications for biotechnology, particularly those driven by innovation in synthetic biology, are expected to further grow the size and reach of the bioeconomy (White House 2012). Often looked to as a means of producing products that would otherwise be difficult to obtain, synthetic biology has already led to new ways of producing pharmaceuticals including opioids and the anti-malarial drug artemisinin. There are significant ongoing efforts to engineer microorganisms to produce fuels, act as detection devices, and clean up toxic spills. Synthetic biology is also seen as a potential means to grow organs for transplant, manipulate the microbiome, and even produce cosmetics. In addition to such application-driven goals, synthetic biology is also advancing the reach and role of science in society by inspiring more people to engage in biological experimentation, such as through the International Genetically Engineered Machine (iGEM) competition or by engaging with community laboratories. This broad array of applications and implications suggests that the potential benefits of synthetic biology are limited only by human creativity and imagination.
  5. The framework developed by the report is shown here. Is a qualitative framework. Note the four factors that go into the analysis and sub-areas. Report appendix also includes illustrative questions that analysts, experts and other can ask themselves to help articulate the issues and form the assessment Analysis of these elements feeds into the overall assessment of the level of concern for a synthetic biology capability. Note that the report’s framework is not intended as a rigid checklist. Also is not a formal threat assessment because committee did not access or assess information on specific actors or their intent (although others could incorporate such information)
  6. Report applies the framework to an assessment of relative levels of concern associated with synthetic biology enabled capabilities in these 3 general areas
  7. This report hopefully contributes to DoD and partner agencies ability to understand, assess and prepare for the capabilities that synthetic biology enables
  8. This figure provides the report’s assessment of relative concern associated with the capabilities assessed Figure - Relative ranking of concerns related to the synthetic biology-enabled capabilities analyzed. At the present time, capabilities toward the top warrant a relatively high level of concern while capabilities toward the bottom warrant a relatively low level of concern. Out of Scope - Comparing risks related to synthetic biology to other types of threats
  9. For the capabilities discussed in the report, The report identifies a number of bottlenecks and barriers…. These areas provide ones that could be monitored for developments that overcome current constraints and may enable new advances This next slide shows the ones identified with pathogen capabilities…..
  10. Summary of how selected examples of convergent technologies may affect challenges of effecting an attack using a synthetic biology-enabled weapon. Shading indicates which attribute each example aligns with most closely. While factors such as scale-up, stability, fidelity, and delivery are likely to continue to pose barriers to the weaponization of biological agents, a number of technological developments could create synergies with synthetic biology capabilities that allow malicious actors to overcome these barriers. examples of convergent technologies at various stages of development may help reduce barriers in various aspects of weaponization. It will be important to monitor future developments in these and other areas to identify and assess vulnerabilities that could facilitate bioweapons development. Such developments might result in significant raising of the level of concern related to the synthetic biology-enabled capabilities examined in this study
  11. General Observations Classical public health measures such as the disease surveillance system are critical to effective mitigation of attacks caused by agents created with synthetic biology. However, synthetic biology provides opportunities to engineer around current system and cases are likely to arise in which the current infrastructure will be insufficient and thus needing enhancement. Biological and chemical defense strategies that are nimble, as well as adaptable to a wide range of threats, are needed because of rapid rates of technological change and uncertainty about which approaches an adversary might pursue. Prevention and Deterrence Risk management strategies based on defined lists of biological agents, such as the Federal Select Agent Program Select Agents and Toxins list, will be insufficient for managing risks arising from the application of synthetic biology. Similarly, while measures to control access to physical materials such as synthetic nucleic acids and microbial strains have merits, such approaches will not be effective in mitigating all types of synthetic biology-enabled attacks. Appropriate preparation for these challenges is needed. Recognition and Attribution The development of more flexible, untargeted, and multi-modal detection technologies such as next-generation sequencing and mass spectrometry analysis will facilitate improved identification capabilities for synthetic biology derived agents. The development of epidemiological methods (e.g., surveillance and data collection) that would strengthen the ability to detect unusual symptoms or aberrant patterns of disease will be useful. Consequence Management Computer-based approaches may provide a number of tools to support the prevention, detection, attribution, and consequence mitigation of threats posed by synthetic biology. Such approaches represent an area for further exploration. Beneficial applications of synthetic biology for countermeasure research and development are expected to provide an opportunity to address concerns raised by synthetic biology, when accompanied by corresponding efforts to facilitate the entire development process, including regulatory considerations.
  12. Developing capabilities to detect unusual ways in which a synthetic biology-enabled weapon may manifest. For consequence management, expanding the development of epidemiological methods (e.g., surveillance and data collection) would strengthen the ability to detect unusual symptoms or aberrant patterns of disease. Enhancing epidemiological methods will have an additional benefit of strengthening the ability to respond to natural disease outbreaks.   Harnessing computational approaches for mitigation. The role of computational approaches for prevention, detection, control, and attribution will become more important with the increasing reliance of synthetic biology on computational design and computational infrastructure. Leveraging synthetic biology to advance detection, therapeutics, vaccines, and other medical countermeasures. Taking advantage of beneficial applications of synthetic biology for countermeasure research and development is expected to prove valuable, along with corresponding efforts to facilitate the entire development process, including regulatory considerations.   REMINDER: A comprehensive, in-depth review of strengths and weaknesses in current U.S. or international programs was outside the scope of this study; as such, this report does not offer a full analysis of mitigation capabilities and makes no recommendations pertaining to mitigation priorities. A comprehensive, in-depth review of strengths and weaknesses in current U.S. or international programs was outside the scope of this study; as such, this report does not offer a full analysis of mitigation capabilities and makes no recommendations pertaining to mitigation priorities. The following observations indicate areas in which additional attention could help address some of the challenges posed by synthetic biology.
  13. What could possibly go wrong? How could you tell if someone in your lab/company was conducting rogue research?